AML was our fastest pathway to approval - or at least it was 2 years ago.
The NPV of RAC would be far greater right now if there was revenue forecast for 2024. I think it was incorrectly designated a 'fall-back' option when it should have been licensed to advance and expedite all programs.
Yes, the new formulation is a great opportunity, but we could have had FTO patient data from dozens of patients by now utilising central line administration.
Ann: Quarterly Activity Report & Appendix 4C, page-43
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |